Zoekresultaten - Portaal voor medische datamodellen (MDM-portaal)

Pazopanib Eye Drops versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration NCT01134055 - Screen - Medical / surgical procedures; Risk Factors; Vital Signs; History of Tobacco Use; Alcohol intake

- 10-01-20 - 1 Formulier, 10 Itemgroepen, 31 Data-elementen, 1 Taal

Itemgroepen: Medical/ surgical procedures - Right Eye, Medical/ surgical procedures - Left Eye , Other ocular surgeries and procedures, Risk Factors, Vital Signs, First sitting BP reading, Second sitting BP reading , Third sitting BP reading , History of Tobacco Use, Alcohol intake

Study ID: 110852 Clinical Study ID: 110852 Study Title: MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01134055 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: pazopanib eye drops, ranibizumab intravitreal injection, placebo Trade Name: pazopanib, ranibizumab Study Indication: Macular Degeneration

Eligibility Tobacco Smoking in Schizophrenic Patients NCT01979796

- 13-07-19 - 1 Formulier, 2 Itemgroepen, 10 Data-elementen, 1 Taal

Itemgroepen: Inclusion Criteria, Exclusion Criteria

Antismoking Effects of Electronic Cigarettes in Subjects With Schizophrenia and Their Potential Influence on Cognitive Functioning.; ODM derived from: https://clinicaltrials.gov/show/NCT01979796

Treatment Visit 2 Month 1 PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes NCT00153062

- 15-02-17 - 1 Formulier, 4 Itemgroepen, 8 Data-elementen, 1 Taal

Itemgroepen: Concomitant Medication, ACE Inhibitors, Restricted Concomitant Medication, Tobacco Use Status

The purpose of the trial is to determine if extended-release dipyridamole + aspirin [Aggrenox, Asasa ntin] is superior to clopidogrel [Plavix], and if telmisartan [Micardis, Gliosartan, Kinzal, Kinzalm ono, Predxal, Pritor, Samertan, Telmisartan] is superior to placebo, in the presence of background antihypertensive therapy, in prevention of a second stroke in patients who have recently suffered a stroke and therefore are at high risk of suffering another one.

Sumatriptan and Naproxen Sodium for Acute Treatment of Migraine Attacks; NCT00792636 - Subject In-Clinic Diary - Screen

- 20-09-21 - 1 Formulier, 6 Itemgroepen, 25 Data-elementen, 1 Taal

Itemgroepen: Administrative documentation, Pharmaceutical Preparations, Subject Diary, Blood Pressure, Exercise, Migraine Disorders, Information, Alcohol consumption, Subject Diary, Caffeine Use, Subject Diary, Tobacco Use, Subject Diary

Study ID: 110948 Clinical Study ID: 110948 Study Title: Assessment of the effect of sumatriptan and naproxen sodium combination tablet, sumatriptan tablet, and naproxen sodium tablet treatment on blood pressure when administered intermittently for six months for the acute treatment of migraine attacks, with or without aura, in adults Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00792636 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 4 Study Recruitment Status: Completed Generic Name: sumatriptan and naproxen sodium combination tablet Trade Name: sumatriptan tablet, naproxen sodium tablet Study Indication: Migraine Disorders

Effect of Lamictal on Resting Motor Threshold Study-ID 107434 - Alcohol and Tobacco Use

- 25-12-18 - 1 Formulier, 4 Itemgroepen, 12 Data-elementen, 1 Taal

Itemgroepen: Administrative Data, Tobacco Use, Alcohol consumption, Conclusion

Study ID: 107434 Clinical Study ID: NAP107434 Study Title: A randomised, double-blind, double-dummy, placebo controlled, three-way cross-over study to investigate the effect of single oral doses of 100 mg GW273225 (4030W92) and 325 mg LAMICTAL on resting motor threshold in healthy subjects Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Study Link: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: GW273225 Trade Name: lamictal Study Indication: Bipolar Disorder This form contains information about the subject's alcohol and tobacco use. It should be filled out at the screening visit. Screening Visit: 28 days prior to first dosing. Treatment Period: The day before dosing, until 48h after dosing. Follow-Up: 14-21 days after last dose

End of Trial Medication Compliance Discontinuation Tobacco Use PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes NCT00153062

- 21-02-17 - 2 Formulieren, 4 Itemgroepen, 12 Data-elementen, 1 Taal

Itemgroepen: Trial Medication Compliance, Discontinuation Of Trial Medication, 5. Discontinuation Of Trial Medication, Tobacco Use Status

The purpose of the trial is to determine if extended-release dipyridamole + aspirin [Aggrenox, Asasa ntin] is superior to clopidogrel [Plavix], and if telmisartan [Micardis, Gliosartan, Kinzal, Kinzalm ono, Predxal, Pritor, Samertan, Telmisartan] is superior to placebo, in the presence of background antihypertensive therapy, in prevention of a second stroke in patients who have recently suffered a stroke and therefore are at high risk of suffering another one. End of Trial Study Source & Descriptions: https://clinicaltrials.gov/ct2/show/NCT00153062?term=NCT00153062&rank=1

F.2

0 Itemgroep 0 Data-element

Penultimate Trial Medication Tobacco Use PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes NCT00153062

- 23-03-17 - 1 Formulier, 4 Itemgroepen, 11 Data-elementen, 1 Taal

Itemgroepen: Trial Medication Compliance, Discontinuation Of Trial Medication, Discontinuation Of Trial Medication, Tobacco Use Status

The purpose of the trial is to determine if extended-release dipyridamole + aspirin [Aggrenox, Asasa ntin] is superior to clopidogrel [Plavix], and if telmisartan [Micardis, Gliosartan, Kinzal, Kinzalm ono, Predxal, Pritor, Samertan, Telmisartan] is superior to placebo, in the presence of background antihypertensive therapy, in prevention of a second stroke in patients who have recently suffered a stroke and therefore are at high risk of suffering another one. Penultimate Visit (Next to last Visit) Study Source & Descriptions: https://clinicaltrials.gov/ct2/show/NCT00153062?term=NCT00153062&rank=1

Tobacco Use Alcohol Consumption PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes NCT00153062

- 16-02-17 - 1 Formulier, 3 Itemgroepen, 17 Data-elementen, 1 Taal

Itemgroepen: 1. Tobacco Use, 2. Type of tobacco use, Alcohol Consumption

The purpose of the trial is to determine if extended-release dipyridamole + aspirin [Aggrenox, Asasa ntin] is superior to clopidogrel [Plavix], and if telmisartan [Micardis, Gliosartan, Kinzal, Kinzalm ono, Predxal, Pritor, Samertan, Telmisartan] is superior to placebo, in the presence of background antihypertensive therapy, in prevention of a second stroke in patients who have recently suffered a stroke and therefore are at high risk of suffering another one. Alcohol consumption: Regular alcohol consumption: respond yes if consumption is >1 drink per week. (1 drink=1 glass beer, 1.5 ounces/50 mis or more of hard liquor or 1 glass of wine).

Sumatriptan pharmacokinetics TREXIMA and IMITREX tablet ID 106396 - Substance Use

- 03-10-18 - 1 Formulier, 5 Itemgroepen, 21 Data-elementen, 1 Taal

Itemgroepen: Administrative Data, Alcohol Intake, Tobacco Use, Drug and Alcohol Screen, Laboratory Tests - Urine Cotinine

This ODM file contains the form to collect data about the substance use of the patient. To be assessed at Screening. Study ID: 106396 Clinical Study ID: TRX106396 Study Title: An open-label, randomized, single-dose, 2-period crossover study to evaluate sumatriptan pharmacokinetics for a TREXIMA™(sumatriptan 85mg and naproxen sodium 500mg)*, Tablet compared with an IMITREX® (sumatriptan) 100mg Tablet Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: sumatriptan Trade Name: Imitrex ,Imiject ,Imigran; Imitrex,Imiject,Imigran Study Indication: Migraine Disorders Sponsor: GlaxoSmithKline

ALCOHOL / TOBACCO USE HISTORY (SCREENING) CRFs Roche FVF4170G Macular Edema NCT-Nummer: NCT00473382

- 08-06-17 - 1 Formulier, 2 Itemgroepen, 15 Data-elementen, 1 Taal

Itemgroepen: Patient administration, ALCOHOL / TOBACCO USE HISTORY (SCREENING)

Terms of use: You may not use this document or the information contained herein to a regulatory authority in connection with an application for a marketing authorization or any other regulatory submission without the express written consent of Roche Study #: FVF4170g Drug: Ranibizumab Study Title: A Phase III, Double-Masked, Multicenter, Randomized, Sham-Controlled Study Of The Efficacy And Safety Of Ranibizumab Injection In Subjects With Clinically Significant Macular Edema With Center Involvement Secondary To Diabetes Mellitus

ALCOHOL / TOBACCO USE HISTORY (SCREENING) CRFs Roche FVF4168G Macular Edema NCT00473330

- 08-06-17 - 1 Formulier, 2 Itemgroepen, 15 Data-elementen, 1 Taal

Itemgroepen: Patient administration, ALCOHOL / TOBACCO USE HISTORY (SCREENING)

Terms of use: You may not use this document or the information contained herein to a regulatory authority in connection with an application for a marketing authorization or any other regulatory submission without the express written consent of Roche Study #: FVF4168g Drug: Ranibizumab Study Title: A Phase III, Double-Masked, Multicenter, Randomized, Sham-Controlled Study Of The Efficacy And Safety Of Ranibizumab Injection In Subjects With Clinically Significant Macular Edema With Center Involvement Secondary To Diabetes Mellitus

Comparison of pharmacokinetic and tolerability of ropinirole in healthy adults, 101468/198 - Smoking History for sessions

- 15-04-19 - 1 Formulier, 2 Itemgroepen, 6 Data-elementen, 1 Taal

Itemgroepen: Administrative data, Smoking history

Study ID: 101468/198 Clinical Study ID: 101468/198 Study Title:An open, randomised, crossover, healthy volunteer study to compare the PK and tolerability of ropinirole as 3 different new formulations with the standard marketed formulation and to study the effects of a high fat meal on a new formulation Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 1 Study Recruitment Status: Completed Generic Name: ropinirole Trade Name: Modutab,ZIPEREVE,ZEPREVE,REPREVE,ADARTREL,REQUIP,Zygara; Zygara,ZIPEREVE,ZEPREVE,Requip Depot,REQUIP,REPREVE,Modutab,ADARTREL Study Indication : Restless Legs Syndrome The Study consists of a Screening, 5 Sessions each with 2 days and a Follow-up. This document contains the smoking history for sessions form. It has to be filled in for all sessions for each day 1 and day 2.

Trefwoorden

Inhoudsopgave

Geselecteerde datamodellen